Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEKS-NP: Cefiderocol vs Meropenem in Nosocomial Pneumonia
NCT03032380Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of cefiderocol in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP) and bacterial pneumonia (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: All-cause Mortality Rate at Day 14. Started Oct 2017; status: completed.
02
Drugs
cefiderocol
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)bacterial pneumonia
Beyond the preview
Go deeper on NCT03032380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03032380.